Cochrane Corner: Hearing aids for mild to moderate hearing loss in adults by Brennan-Jones, Christopher G. et al.
1 
 
Cochrane Corner: Hearing aids for mild to moderate hearing loss in 
adults  
 
Authors: 
Christopher G. Brennan-Jones,1,2,3  
Elizabeth Weeda, 2  
Melanie Ferguson, 4,5  
 
1. Ear Health Group, Telethon Kids Institute, The University of Western Australia  
2. Division of Paediatrics, UWA School of Medicine, The University of Western 
Australia  
3. Department of Audiology, Perth Children’s Hospital, Nedlands, Western Australia  
4. NIHR Nottingham Biomedical Research Centre, Division of Clinical Neuroscience, 
School of Medicine, University of Nottingham, Nottingham, UK  
5. Nottingham University Hospitals NHS Trust, Nottingham, UK  
 
Contact:  
Dr Chris Brennan-Jones  
Telethon Kids Institute, The University of Western Australia  
E: chris.brennan-jones@telethonkids.org.au  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Abstract  
This Cochrane Corner features the review entitled “Hearing aids for mild to moderate 
hearing loss in adults” published in 2017. In their review, Ferguson et al. identified 
five randomised controlled trials (RCTs) involving 825 participants, with moderate 
quality of evidence shown for all domains except adverse effects. Results showed a 
large beneficial effect of hearing aids on hearing-specific health-related quality of life 
and listening ability, and a small yet significant beneficial effect on overall health 
related quality of life. Ferguson et al. concluded that according to the available 
evidence, hearing aids are effective at improving hearing-specific health-related 
quality of life, general health related quality of life and listening ability in adults with 
mild to moderate hearing loss. The evidence supports the widespread provision of 
hearing aids as the first-line clinical management for those seeking help for hearing 
difficulties.  
 
Background  
Hearing aids are a routine treatment for patients suffering from hearing loss. 
Whilst alternative interventions exist for hearing loss, including rehabilitation and 
communication programs that support self-management and other assistive hearing 
devices, hearing aids are the most widely used treatments for mild to moderate 
hearing loss. However, despite this, non-use of hearing aids varies from 3% (Bertoli 
et al., 2009) to 24% (Lupsakko et al., 2005). For those that do use their hearing aids, 
typical daily usage is for 8 to 12 hours and there are no significant differences in 
hearing aid use for adults with mild or moderate hearing loss, nor is age or gender a 
significant predictor of daily hearing aid usage (Timmer et al., 2017). Hearing loss 
increases with age (Akeroyd et al., 2014), and with an ageing population the number 
of people suffering from hearing loss will continue to increase along with the quality 
of life and economic burdens associated with this condition (Mathers, 2008).This 
makes it ever more important to examine the evidence base for a common 
intervention, such as hearing aids, to establish whether this intervention provides a 
sufficient improvement in quality of life and other key outcome measures. A 
Cochrane review by Ferguson et al. (2017) investigates this important topic by 
examining the effectiveness of hearing aids for adults with mild to moderate hearing 
loss.  
 
3 
 
The primary outcomes for this Cochrane review were hearing-specific health-
related quality of life, with participation as the key domain, and pain associated with 
hearing aids. Secondary outcomes of interest were health-related quality of life, 
functional measure of listening ability, and adverse effects of noise-induced hearing 
loss. The review included five RCTs (825 participants) from USA and Europe 
published between 1987 and 2017. To measure hearing-specific quality of life all 
studies used the Hearing Handicap Inventory for the Elderly (HHIE), and found a 
large effect size that favoured hearing aids. The World Health Organization Disability 
Assessment Schedule II (WHO-DAS II) and Self Evaluation of Life Function (SELF) 
questionnaires were used to measure health-related quality of life, and a small but 
significant beneficial effect size of hearing aids was shown. Listening ability was 
measured with either the Profile of Hearing Aid Performance (PHAP) or Abbreviated 
Profile of Hearing Aid Benefit (APHAB) measures and a large beneficial effect of 
hearing aids was shown. As Ferguson et al. reported, there was inconsistent use of 
outcome measures. Only one study attempted to measure adverse effects and reported 
no adverse pain or noise-induced hearing loss with hearing aids, therefore there is 
little information to adequately assess the risk of adverse events. For an intervention 
that is so widespread, there is a surprising paucity of high-quality trials evaluating its 
benefit – as is evidenced by the inclusion of only 5 RCTs in the Ferguson et al. 
review.  
 
Cochrane review abstract from Ferguson et al (2017) 
Background 
The main clinical intervention for mild to moderate hearing loss is the provision of 
hearing aids. These are routinely offered and fitted to those who seek help for hearing 
difficulties. By amplifying and improving access to sounds, and speech sounds in 
particular, the aim of hearing aid use is to reduce the negative consequences of 
hearing loss and improve participation in everyday life. 
 
Objectives 
To evaluate the effects of hearing aids for mild to moderate hearing loss in adults. 
Search methods 
The Cochrane ENT Information Specialist searched the ENT Trials Register; the 
Cochrane Register of Studies Online; MEDLINE; PubMed; EMBASE; 
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CINAHL;Web of Science; ClinicalTrials.gov; ICTRP and additional sources for 
published and unpublished trials. The date of the search was 23 March 2017. 
Selection criteria 
Randomised controlled trials (RCTs) of hearing aids compared to a passive or active 
control in adults with mild to moderate hearing loss. 
Data collection and analysis 
We used the standard methodological procedures expected by Cochrane. The primary 
outcomes in this review were hearing-specific health-related quality of life and the 
adverse effect pain. Secondary outcomes were health-related quality of life, listening 
ability and the adverse effect noise-induced hearing loss. We used GRADE to assess 
the quality of the evidence for each outcome; this is indicated in italics. 
Main results 
We included five RCTs involving 825 participants. The studies were carried out in the 
USA and Europe, and were published between 1987 and 2017. Risk of bias across the 
studies varied. Most had low risk for selection, reporting and attrition bias, and a high 
risk for performance and detection bias because blinding was inadequate or absent. 
All participants had mild to moderate hearing loss. The average age across all five 
studies was between 69 and 83 years. The duration of the studies ranged between six 
weeks and six months. 
There was a large beneficial effect of hearing aids on hearing-specific health-related 
quality of life associated with participation in daily life as measured using the Hearing 
Handicap Inventory for the Elderly (HHIE, scale range 1 to 100) compared to the 
unaided/placebo condition (mean difference (MD) -26.47, 95% confidence interval 
(CI) -42.16 to -10.77; 722 participants; three studies) (moderate-quality evidence). 
There was a small beneficial effect of hearing aids on general health-related quality of 
life (standardised mean difference (SMD) -0.38, 95% CI -0.55 to -0.21; 568 
participants; two studies) (moderate-quality evidence). There was a large beneficial 
effect of hearing aids on listening ability (SMD -1.88, 95% CI -3.24 to -0.52; 534 
participants; two studies) (moderate-quality evidence). 
Adverse effects were measured in only one study (48 participants) and none were 
reported (very low-quality evidence). 
Authors’ conclusions 
The available evidence concurs that hearing aids are effective at improving hearing-
specific health-related quality of life, general health related quality of life and 
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listening ability in adults with mild to moderate hearing loss. The evidence is 
compatible with the widespread provision of hearing aids as the first-line clinical 
management in those who seek help for hearing difficulties. Greater consistency is 
needed in the choice of outcome measures used to assess benefits from hearing aids. 
Further placebo-controlled studies would increase our confidence in the estimates of 
these effects and ascertain whether they vary according to age, gender, degree of 
hearing loss and type of hearing aid. 
 
Comments 
One of the key aims of the IJA Cochrane Corner is to gain some additional 
insights into the implications of Cochrane reviews for clinical practice. Each review is 
a significant undertaking to the authorship teams, and they are essential in developing 
the evidence-base within audiology. Here we discuss some of the key clinical 
implications of this review with lead author Dr Ferguson.  
 
Brennan-Jones: Your findings that evidence supports the use of hearing aids will not 
come as a shock to most audiologists, so why was it important to do this review? 
Ferguson: Yes, this has been pointed out by quite a few people already! There are 
three pillars to evidence-based practice one of which is individual clinical expertise 
(e.g. the audiologist), the other two are patient values and preferences, and research 
evidence Sackett et al., 2000). Here, we are presenting the research evidence based on 
the published literature. As you know, systematic reviews including meta-analyses 
provide the highest level of evidence when considering evidence hierarchy and 
scientific rigour, with Cochrane reviews as the ‘gold standard’. The review itself was 
prompted for two reasons. First, the previous systematic review on hearing aids 
included studies that were published up until 2004 (Chisolm et al., 2007), so more 
than a decade on it seemed that the time was right to update the evidence from the 
published literature. Second, in 2014 a number of clinical commissioning groups, who 
commission and pay for UK National Health Service (NHS) healthcare, considered 
withdrawing the provision of hearing aids for adults with mild and/or moderate 
hearing loss. Hearing aids in the UK have been provided free at the point of delivery 
to those who need them since the inception of the NHS in 1948. It was clear there was 
a need for high-quality, up-to-date evidence on the effectiveness of hearing aids for 
adults with mild to moderate hearing loss. I should add that a more recent systematic 
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review of hearing aids for adults with mild hearing loss was published (Johnson et al., 
2016). However, there were no randomised controlled trials (RCTs) in that review, 
and we were only interested in RCTs, the highest level of primary research evidence. 
 
Brennan-Jones: What impact do you think this review could or should have on the 
way we deliver clinical services for those with mild to moderate hearing loss? 
Ferguson: I think that our conclusion that “the evidence is compatible with the 
widespread provision of hearing aids as the first-line clinical management in those 
seeking help for hearing difficulties” says it all. The evidence, which was moderate 
quality in all domains except adverse effects, suggests that if people seek help for 
their hearing difficulties and wear hearing aids, there will be benefits in listening 
ability, participation in everyday life, and importantly as this had not been shown 
clearly before, health-related quality of life. We were unable to look at mild and 
moderate hearing loss separately as the data were not available, so for now and until 
there is more published evidence on this, those with mild to moderate hearing loss are 
likely to benefit in the outcome domains we specified. It’s probably worth noting here 
that while Cochrane reviews provide the evidence, they don’t provide clinical 
recommendations as such. That lies within the realms of organisations such as the 
UK’s National Institute for Health and Care Excellence (NICE). Currently, guidelines 
for adult-onset hearing loss are being developed and will be published in May 2018 
(see https://www.nice.org.uk/guidance/gid-cgwave0833/documents/html-content-2 
for draft consultations), and this review forms the basis of the recommendation to 
offer hearing aids to adults whose hearing loss affects their communication abilities. 
So overall, I think this review will be impactful, both in the UK and elsewhere. There 
is a lot of discussion at the moment about ‘over-the-counter’ (OTC) models of 
delivery, particularly in the United States following their National Academies of 
Science report)(National Academies of Science, 2016). There needs to be a good 
evidence-base for any new models of service delivery. Humes et al (2017), one of our 
included studies, provide some good and relevant evidence, but as they say, their 
evidence is specific to the hearing aids, and population reported.   
 
Brennan-Jones: You mention that more consistent use of outcome measures in future 
studies would be beneficial. We are lucky to have a range of hearing-specific health-
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related quality of life measures. Which outcome measure(s) should prospective 
clinicians and researchers be using to evaluate their programs? 
Ferguson: This is the 64,000 dollar question! I’m not sure ‘lucky’ is the word I 
would use about the raft of outcome measures that are out there. The systematic 
review by Granberg et al (2014) reported that 51 self-report questionnaires had been 
used in 122 adult hearing loss studies (and even more behavioural outcome measures, 
such as speech testing). Just one instrument had been used twice, and the HHIE, 
which was the most commonly used self-report measure, was only used 5 times in the 
studies included in their review. Another study identified 139 hearing-specific 
questionnaires (Akeroyd et al., 2015). The use of many questionnaires means that it is 
difficult to decide on the primary outcome measure for clinical trials and conduct 
meta-analyses for systematic reviews across studies (although we were able to do this 
for hearing-specific health-related quality of life using the HHIE). In part, this is 
because the consequences of hearing loss are complex and multifactorial. The use of a 
Core Outcome Set (COS) is one method that is suggested can standardise outcome 
measurement. A COS is a collection of outcomes for a particular condition that key 
stakeholders agree are critically important when deciding whether an intervention has 
worked or not. Currently, a COS is being identified for tinnitus (Hall et al., 2015)  and 
for cochlear implants, and we are working towards developing a COS for adults with 
sensorineural hearing loss. So for now, I think the jury is out. However, in terms of 
hearing-specific health-related quality of life, we now include the HHIE in our studies 
for the reasons given above. In terms of health-related quality of life, questionnaires 
such as the WHO-DAS 2.0 (which has superseded the WHO-DAS II) and the Health 
Utilities Index Mk III, which include some aspects of quality of life specific to 
hearing, are more likely to show effects of hearing-related interventions than more 
generic measures such as the EQ-5D (McArdle et al., 2005, Chisolm et al., 2005, 
Barton et al., 2004, Davis et al., 2007). 
 
Weeda: Some studies included in this review were published in the 1980s. Given the 
progress in technology over that time, can outcomes from recent studies be compared 
to outcomes of hearing aids of 30 years ago? 
Ferguson: That’s a very good question. We can see in our review that the Humes et 
al (2017) study showed a smaller although still large effect size of hearing aids on the 
HHIE compared to the two older studies (Mulrow et al., 1990, McArdle et al., 2005) 
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in our post-hoc analysis. This resulted in high heterogeneity (97%). There were many 
differences between these studies, which we discuss in the review. For example, 
different populations (US Department of Veteran Affairs (VA) clients vs community 
dwellers), gender split (veterans were mainly male – versus community dwellers 
which had a more even male:female split), in-the-ear and behind-the-ear hearing aid 
provision, and whether they were provided at no cost (VA clients) or purchased 
(community), or controls who had no hearing aids (VA clients) compared to placebo 
hearing aids (Humes et al., 2017, Adrait et al., 2017) thereby minimising the effects of 
intervention and outcomes blinding, and poorer hearing thresholds in the VA samples 
compared to the community dwellers. On the basis of the evidence we had, we were 
unable to say what caused these differences. If we want to drill down to establish 
what the effects these numerous factors have on outcomes, we would need to conduct 
well-designed trials, which we discuss in the Implications for Research.   
 
Weeda: The inclusion of a study where all participants have Alzheimer’s disease is of 
interest. This is an important, increasing and sometimes challenging clinical 
population; are the results comparable to populations with typical cognitive function? 
Ferguson: The study on participants with Alzheimer’s Disease was a well-conducted 
study, with limited risk of bias. However, this study showed no effect of hearing aids 
on the primary outcome, a neuropsychological test battery (Adrait et al., 2017) or 
other cognitive measures (Nguyen et al., 2017). The sample was quite small (N=48), 
and the average age was 83 years, about 10 years greater than the average for first-
fitting of hearing aids. The participant sample in this study in terms of cognitive status 
was very different to those of the included studies (i.e. Alzheimer’s disease vs normal 
cognitive function), so no, I don’t think they are comparable. There is an ongoing 
study on Alzheimer’s disease (NCT03002142) and other studies are likely to look at 
this over the coming years. It may be that fitting hearing aids to adults with hearing 
loss in mid-life as part of a longitudinal study would show some beneficial effects of 
hearing aids on cognitive decline, as hearing loss has been identified in a recent 
review commissioned by The Lancet to be the top modifiable risk for dementia 
(Livingston et al., 2017) – but this is merely speculation. High-quality RCTs are 
needed to measure and understand the benefits of hearing aids in this population and 
in those with mild cognitive decline to answer this question.  
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Conclusion  
This review by Ferguson et al. (2017) offers a comprehensive overview of the 
evidence for prescription of hearing aids and highlights the lack of consensus in the 
literature regarding outcome measures for hearing research. The review provides 
robust recommendations for the use of hearing aids in mild to moderate hearing loss, 
supporting current clinical practice. 
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